Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-047/00
출원번호
US-0601005
(1995-12-19)
우선권정보
SE-0002452 (1995-07-06); SE-0004469 (1994-12-22)
국제출원번호
PCT//SE95/01542
(1997-03-01)
§371/§102 date
19970301
(19970301)
국제공개번호
WO96//19198
(1996-06-27)
발명자
/ 주소
B?ckstr?m, Kjell
Dahlb?ck, Magnus
Johansson, Ann
K?llstrand, G?ran
Lindqvist, Elisabet
출원인 / 주소
AstraZeneca AB
대리인 / 주소
Fish &
인용정보
피인용 횟수 :
40인용 특허 :
84
초록
Aerosol formulations suitable for use in pressurised metered dose inhalers comprise a hydrofluoroalkane propellant, an medicament for inhalation and a surfactant which is a a C8?C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide.
대표청구항▼
1. A pharmaceutical aerosol formulation comprising a hydrofluoroalkane (HFA) propellant; a physiologically effective amount of a medicament for inhalation; and an alkyl saccharide surfactant, wherein the medicament and the surfactant are suspended in the propellant as a finely divided powder.2. A ph
1. A pharmaceutical aerosol formulation comprising a hydrofluoroalkane (HFA) propellant; a physiologically effective amount of a medicament for inhalation; and an alkyl saccharide surfactant, wherein the medicament and the surfactant are suspended in the propellant as a finely divided powder.2. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the surfactant is selected from the group consisting of an alkyl glucoside and an alkyl maltoside.3. A pharmaceutical aerosol formulation as claimed in claim 2, wherein the surfactant is selected from the group consisting of decyl glucoside and dodecyl maltoside.4. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the formulation comprises a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane (P134a), 1,1,1,2,3,3,3-heptafluoropropane (P227), or 1,1-difluoroethane (P152a).5. The pharmaceutical aerosol formulation as claimed in claim 4, wherein the surfactant is decyl glucoside.6. The pharmaceutical aerosol formulation as claimed in claim 4, wherein the surfactant is dodecyl maltoside.7. A pharmaceutical aerosol formulation as claimed in claim 4, wherein the formulation comprises a propellant mixture comprising 1,1,1,2-tetrafluoroethane (P134a) and 1,1,1,2,3,3,3-heptafluoropropane (P227).8. A pharmaceutical aerosol formulation as claimed in claim 7, wherein the formulation comprises a density-matched propellant mixture of 1,1,1,2-tetrafluoroethane (P134a) and 1,1,1,2,3,3,3-heptafluoropropane (P227).9. The pharmaceutical aerosol formulation as claimed in claim 7, wherein the surfactant is decyl glucoside.10. The pharmaceutical aerosol formulation as claimed in claim 7, wherein the surfactant is dodecyl maltoside.11. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the medicament is selected from the group consisting of a β2-adrenoreceptor agonist, an anticholinergic bronchodilator, and a glucocorticosteroid.12. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the medicament is selected from the group consisting of salbutamol, terbutaline, rimiterol, fenoterol, reproterol, adrenaline, pirbuterol, isoprenaline, orciprenaline, bitolterol, salmeterol, formoterol, clenbuterol, procaterol, broxaterol, picumeterol, mabuterol, ipratropium bromide, beclomethasone, fluticasone, budesonide, tipredane, dexamethasone, betamethasone, fluocinolone, triamcinolone acetonide, mometasone, and pharmacologically acceptable esters and salts thereof.13. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the medicament is selected from the group consisting of anti-allergic medicaments, expectorants, mucolytics, antihistamines, cyclooxygenase inhibitors, leukotriene synthesis inhibitors, leukotriene antagonists, phospholipase-A2 (PLA2) inhibitors, platelet aggregating factor (PAF) antagonists, prophylactics of asthma, antiarrhythmic medicaments, tranquilisers, cardiac glycosides, hormones, anti-hypertensive medicaments, antidiabetic medicaments, antiparasitic medicaments, anticancer medicaments, sedatives, analgesic medicaments, antibiotics, antirheumatic medicaments, immunotherapeutic agents, antifungal medicaments, antihypotension medicaments, vaccines, antiviral medicaments, proteins, peptides, vitamins, cell surface receptor blockers, antioxidants, free radical scavengers, and organic salts of N,N′-diacetylcystine.14. A pharmaceutical aerosol formulation as claimed in claim 1, including ethanol in an amount of up to 20% by weight of propellant and surfactant.15. A pharmaceutical aerosol formulation as claimed in claim 1, including ethanol in an amount of up to 5% by weight of propellant and surfactant.16. A pharmaceutical aerosol formulation as claimed in claim 1, further comprising a substance selected from the group consisting of adjuvants, carriers, flavouring agents, buffers, antioxidants and chemical stabilisers.17. A pharmaceutical aerosol formulation as claimed in claim 1, wherein at least 50% of the medicament consists of particles having a diameter of 0.01?10 microns.18. A pharmaceutical aerosol formulation as claimed in claim 17, wherein at least 70% of the medicament consists of particles having a diameter of 0.01?10 microns.19. A pharmaceutical aerosol formulation as claimed in claim 17, wherein at least 90% of the medicament consists of particles having a diameter of 0.01?10 microns.20. A pharmaceutical aerosol formulation as claimed in claim 1, wherein at least 50% of the medicament consists of particles having a diameter of 0.1?6 microns.21. A pharmaceutical aerosol formulation as claimed in claim 20, wherein at least 70% of the medicament consists of particles having a diameter of 0.01?6 microns.22. A pharmaceutical aerosol formulation as claimed in claim 20, wherein at least 90% of the medicament consists of particles having a diameter of 0.01?6 microns.23. A pharmaceutical aerosol formulation as claimed in claim 1, wherein at least 50% of the medicament consists of particles having a diameter of 0.1?5 microns.24. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the concentration of medicament in the formulation is 0.1 mg/ml to 25 mg/ml.25. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the ratio of surfactant to medicament is in the range of 1:50 to 1:0.2.26. A pharmaceutical aerosol formulation as claimed in claim 1, the formulation comprising a physiologically effective amount of each of a β2-adrenoreceptor agonist and a glucocorticosteriod.27. A pharmaceutical aerosol formulation as claimed in claim 26, further comprising a physiologically effective amount of an anticholinergic bronchodilator.28. A pharmaceutical aerosol formulation as claimed in claim 1, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) budesonide, or a salt, ester, solvate, or solvate of a salt or ester thereof.29. A pharmaceutical aerosol formulation as claimed in claim 1, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) mometasone, or a salt ester, solvate, or solvate of a salt or ester therefor.30. A pharmaceutical aerosol formulation as claimed in claim 1, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.31. A pharmaceutical aerosol formulation as claimed in claim 1, the formulation comprising a physiologically effective amount of each of (a) salmeterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.32. The pharmaceutical aerosol formulation as claimed in claim 1, wherein the surfactant is decyl glucoside.33. The pharmaceutical aerosol formulation as claimed in claim 1, wherein the surfactant is dodecyl maltoside.34. A pharmaceutical aerosol formulation as claimed in claim 1, the formulation comprising a physiologically effective amount of each of (a) formoterol and (b) budesonide.35. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the formulation comprises a physiologically effective amount of each of (a) an anticholinergic bronchodilator and (b) a β2-adrenoreceptor agonist.36. A pharmaceutical aerosol formulation as claimed in claim 1, wherein the formulation comprises a physiologically effective amount of each of (a) an anticholinergic bronchodilator and (b) a glucocorticosteroid.37. A method for the manufacture of a pharmaceutical aerosol formulation as claimed in claim 1, comprising the steps of:providing a mixture of the medicament and the surfactant in a vessel;adding hydrofluoroalkane (HFA) propellant to the vessel; andmixing the propellant with the medicament/surfactant mixture to produce a medicament/surfactant/propellant mixture in which the medicament and the surfactant are suspended in the propellant as a finely divided powder.38. The method of claim 37, further comprising the step of mixing additional HFA propellant with the medicament/surfactant/propellant mixture to produce a further mixture in which the medicament and the surfactant are suspended in propellant as a finely divided powder.39. A method for the treatment of a patient in need of therapy with an inhaled medicament, comprising administering to said patient a therapeutically effective amount of a pharmaceutical aerosol formulation comprising a HFA propellant; a physiologically effective amount of a medicament for inhalation; and an alkyl saccharide surfactant, wherein the medicament and the surfactant are suspended in the propellant as a finely divided powder.40. The method of claim 39, wherein the formulation comprises a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane (P134a), 1,1,1,2,3,3,3-heptafluoropropane (P227), and 1,1-difluoroethane (P152a).41. The method of claim 39, wherein the surfactant is selected from the group consisting of an alkyl glucoside and an alkyl maltoside.42. The method of claim 39, wherein the medicament is selected from the group consisting of a β2-adrenoreceptor agonist, an anticholinergic bronchodilator, and a glucocorticosteroid.43. The method of claim 39, wherein the medicament is selected from the group consisting of anti-allergic medicaments, expectorants, mucolytics, antihistamines, cyclooxygenase inhibitors, leukotriene synthesis inhibitors, leukotriene antagonists, phospholipase-A2 (PLA2) inhibitors, platelet aggregating factor (PAF) antagonists, prophylactics of asthma, antiarrhythmic medicaments, tranquilisers, cardiac glycosides, hormones, anti-hypertensive medicaments, antidiabetic medicaments, antiparasitic medicaments, anticancer medicaments, sedatives, analgesic medicaments, antibiotics, antirheumatic medicaments, immunotherapeutic agents, antifungal medicaments, antihypotension medicaments, vaccines, antiviral medicaments, proteins, peptides, vitamins, cell surface receptor blockers, antioxidants, free radical scavengers, and organic salts of N,N′-diacetylcystine.44. The method of claim 39, wherein the ratio of surfactant to medicament is in the range of 1:50 to 1:0.2.45. The method of claim 39, wherein the formulation comprises a physiologically effective amount of each of a β2-adrenoreceptor agonist and a glucocorticosteriod.46. The method of claim 45, wherein the formulation further comprises a physiologically effective amount of an anticholinergic bronchodilator.47. The method of claim 39, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) budesonide, or a salt, ester, solvate, or solvate of a salt or ester thereof.48. The method of claim 39, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) mometasone, or a salt ester, solvate, or solvate of a salt or ester therefor.49. The method of claim 39, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.50. The method of claim 39, wherein the formulation comprises a physiologically effective amount of each of (a) salmeterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.51. The method of claim 39, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol and (b) budesonide.52. The method of claim 39, wherein the formulation comprises a physiologically effective amount of each of (a) an anticholinergic bronchodilator and (b) a β2-adrenoreceptor agonist.53. The method of claim 39, wherein the formulation comprises a physiologically effective amount of each of (a) an anticholinergic bronchodilator and (b) a glucocorticosteroid.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (84)
Meezan Elias (Birmingham AL) Pillion Dennis J. (Birmingham AL), Absorption enhancers for drug administration.
Alexander Jose (Lawrence KS) Fix Joseph A. (Lawrence KS) Repta A. J. (Lawrence KS), Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingua.
Alexander Jose (Lawrence KS) Repta A. J. (Lawrence KS) Fix Joseph A. (Lawrence KS), Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingua.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Stanley Theodore H. (Salt Lake City UT) Hague Brian (West Valley City UT), Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments.
Newhouse Michael T. (436 Queen Street South Hamilton ; Ontario CAX L8N 4A6) Baines W. Douglas (1675 Wedmore Way Mississauga ; Ontario CAX), Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow.
Radhakrishnan Ramachandran (Fremont CA) Mihalko Paul J. (Fremont CA) Abra Robert M. (San Francisco CA), Method and apparatus for administering dehydrated liposomes by inhalation.
Hora Maninder Singh ; Rubinfeld Joseph ; Stern Warren ; Wong Gregory J., Method and compositions for solubilization and stabilization of polypeptides, especially proteins.
Greenleaf David J. (Loughborough GB3) Purewal Tarlochan S. (Leamington Spa GB3) Jinks Philip A. (Mount Sorrel GB3), Method for preparing medicinal aerosol formulation containing coated medicament.
Weiner Howard L. ; Eisenberth George ; Hafler David Allen ; Zhang Zhengi, Method of treating or preventing type 1 diabetes by oral administration of insulin.
Fassberg Julianne (New York NY) Sequeira Joel A. (New York NY) Chaudry Imtiaz A. (North Caldwell NJ) Kopcha Michael (East Brunswick NJ), Non-chlorofluorocarbon aerosol formulations.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Processes for preparing compositions for inhalation.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Benson Bradley J. (170 Cresta Vista Dr. San Francisco CA 94127) Wright JoRae (170 Cresta Vista Dr. San Francisco CA 94127), Pulmonary administration of pharmaceutically active substances.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Backstrom Kjell Goran Erik (Lund SEX) Dahlback Carl Magnus Olof (Lund SEX) Edman Peter (Bjarred SEX) Johansson Ann Charlotte Birgit (Lund SEX), Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Longenecker John P. (Mountain View CA) Ennis Richard (Fremont CA) Baldwin Patricia A. (Hayward CA) Lee William A. (Los Altos CA), Transmembrane formulations for drug administration.
Sequeira Joel A. ; Cuss Francis M. ; Nolop Keith B. ; Chaudry Imtiaz A. ; Nagabhushan Nagamani ; Patrick James E. ; Cayen Mitchell, Use of mometasone furoate for treating upper airway passage diseases.
Schultz Robert K. (Shoreview MN) Quessy Stephen N. (St. Paul MN), Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations.
Sullivan, John K.; McGivern, Joseph G.; Miranda, Leslie P.; Nguyen, Hung Q.; Walker, Kenneth W.; Hu, Shaw-Fen Sylvia; Gegg, Jr., Colin V., DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.